GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » COGS-to-Revenue

LTR Pharma (ASX:LTP) COGS-to-Revenue : 0.00 (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma COGS-to-Revenue?

LTR Pharma's Cost of Goods Sold for the six months ended in Jun. 2023 was A$0.00 Mil. Its Revenue for the six months ended in Jun. 2023 was A$0.00 Mil.

LTR Pharma's COGS to Revenue for the six months ended in Jun. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. LTR Pharma's Gross Margin % for the six months ended in Jun. 2023 was N/A%.

LTR Pharma COGS-to-Revenue Historical Data

The historical data trend for LTR Pharma's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma COGS-to-Revenue Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23
COGS-to-Revenue
- - -

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23
COGS-to-Revenue - - -

LTR Pharma COGS-to-Revenue Calculation

LTR Pharma's COGS to Revenue for the fiscal year that ended in Jun. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

LTR Pharma's COGS to Revenue for the quarter that ended in Jun. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma  (ASX:LTP) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

LTR Pharma's Gross Margin % for the six months ended in Jun. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

LTR Pharma COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of LTR Pharma's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

LTR Pharma (ASX:LTP) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » COGS-to-Revenue
Comparable Companies
Traded in Other Exchanges
N/A
Address
9A/204 Alice Street, Brisbane, QLD, AUS, 4000
Website
https://www.ltrpharma.com
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines